New drug shows promise in early trial for advanced cancers
NCT ID NCT05240898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study aimed to control tumor growth and gather important safety data for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Maine, 48201-2013, United States
-
Cleveland Clinic,
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Mary Crowley Medical Research Center
Dallas, Texas, 75230, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02906, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 98229, United States
-
South Texas Accelerated Research Therapeutics (START) - Midwest Location
Grand Rapids, Michigan, 49546, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
University of California Irvine Medical Center
Orange, California, 92868, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Yale School of Medicine
New Haven, Connecticut, 06510-3206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?